~.-Bisphosphonates are well antirresorptive known drugs, the antiosteoclastic effect of which has been recently suggested to be brought at ]east in part through osteoblasts. Based on this, we have studied the effect of etidronate on the production of IL-I, TNF and IL-6 by peripheral blood mononuclear cells (PBMC) and MG63 cells. For comparison, two other antirresorptive drugs (estradiol and calcitonin} were included in the study. Methods.-PBMC were stimulated with LPS from E. Coli an-~-d--w-i 'h PMA. MG63 cells were stimulated ~ith LP~ and rh dL-] Etidronate was tested at to lO~n, ]0-a and IO-~M. 17 estradiol was tested at IO -'~, .lO "~ an~ IO-M. Human calcitonin was tested at 3xlO -~, 3xlOand 3xlO-M. IL-was measured by IRMA, and TNF and IL-6 by ELISA. Results.-No significant effect of any drug on the ~on of any cytokine by PBMC was found. In MG63 cells, an inhibition of IL-6 production by LPS stimulated (but not by IL-l stimulated) cultures was shown with etidronate, with a 54+1~% inhibition at the maximal tested concentration (F 0-M). No effect was shown by either estradioI or caIcitonin.Conclusion.-Our study support the contention that could bring about part of thei~ antirresorptive effect through the inhibition of IL-6 production by osteoblasts.
BackgroundLipid profiles appear to be altered in rheumatoid arthritis (RA) patients due to disease activity and inflammation. Cholesterol efflux capacity (CEC) has not only been linked to cardiovascular events in the general population, but also to be impaired in RA patients.ObjectivesTo analyze whether CEC is related to subclinical atherosclerosis, as determined by the presence of carotid plaque or increased levels of carotid intima-media thickness (cIMT) in RA patients. Secondarily, we aimed to describe the disease-contributing factors that are related to CEC as an expression of the abnormalities in the lipid profile associated with the disease.MethodsCross-sectional study that encompassed 401 individuals; 178 patients with RA and 223 sex-matched controls. CEC was measured using an in vitro assay, lipoproteins serum concentrations, and standard lipid profile were assessed in patients and controls. Carotid intima-media thickness and carotid plaques were assessed in RA patients. A multivariable analysis was performed to evaluate the relation of CEC with RA-related data, lipid profile and subclinical carotid atherosclerosis.ResultsMean CEC was not significantly different between RA patients (18.9 ± SD 9.0%) and controls (16.9±10.4%), p=0.11. Demographic variables were not associated with CEC except for a correlation with male gender that was only found in RA patients, but not in controls. Systolic blood pressure inversely correlated with CEC in controls (beta coefficient -0.1 [-0.2–0.0] %, p=0.025). In RA patients, a similar trend was found although a statistically significant difference was not reached. Neither the traditional cardiovascular risk factors nor the cardiovascular co-morbidity-related data were associated with CEC. Similarly, lipid profile did not show any relationship with CEC in patients or controls. ESR tended to be associated with a lower CEC although it did not reach statistical significance. RA patients with low (beta coef. -5.2 [-10.0–0.3] %, p=0.039) and moderate disease activity (beta coef. -4.6 [-8.5–0.7] %, p=0.020) were associated with inferior levels of CEC when compared to patients in remission. CEC was not found to be associated with cIMT in RA patients. However, higher CEC was associated with a protective effect for the presence of carotid plaque in RA patients. This relationship was maintained even after multivariate analysis (OR 0.94 [0.89–0.98], p=0.015).ConclusionsOur study, which includes the largest series of RA patients ever assessed for CEC, reveals for the first time that CEC is related to subclinical atherosclerosis in RA patients. The fact that CEC is also associated with disease activity reinforces the idea that CEC may be a mediator between disease activity and subclinical atherosclerosis.Disclosure of InterestNone declared
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.